Clinical Trials · NCT05359146
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
- Phase
- EARLY_Phase 1
- Recruitment status
- Unknown
- Sponsor
- University Hospital, Basel, Switzerland
- Enrollment
- 16
- Start date
- Mar 2023
- Locations
- 1 site, Switzerland
- Primary endpoint
- Change in bone marrow doses after sequential injection of a non-therapeutic test activity of 161Tb-DOTA-LM3 and 177Lu-DOTATOC in the same patients.